Investment Landscape: Parkinson's Disease covers the current R&D investment,
clinical trial pipeline, and funding trends for Parkinson's Disease research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 4613
Active Trials (Recruiting/Active): 1061
| Phase | Count |
|---|---|
| PHASE1 | 337 |
| PHASE1, PHASE2 | 108 |
| PHASE2 | 485 |
| PHASE2, PHASE3 | 54 |
| PHASE3 | 253 |
| PHASE4 | 184 |
| NA | 2006 |
| Not Applicable | 1128 |
| Status | Count |
|---|---|
| RECRUITING | 684 |
| ACTIVE_NOT_RECRUITING | 148 |
| NOT_YET_RECRUITING | 229 |
| COMPLETED | 2369 |
| TERMINATED | 250 |
| WITHDRAWN | 106 |
Parkinson's disease has 4,613 total clinical trials with 1,061 currently active. The Phase 3 portfolio (253 trials) is substantially smaller than Phase 2 (485), indicating a bottleneck in late-stage clinical development. This gap represents a critical investment opportunity.
The high number of terminated trials (250) highlights the need for novel approaches. LRRK2 inhibitors remain a major focus given the genetic link to sporadic PD. GBA-targeted therapies are emerging for the significant subset of patients with GBA mutations. Inflammatory modulation targeting NLRP3 and other inflammasome components represents a promising new frontier.
Only 5.5% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01